Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylic Acid SCHEMBL7066 | 0.84 | CYP2C9 (0.74) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL9568239 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL868225 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL2810363 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL5705762 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL1680669 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL11049826 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL1681667 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL20957595 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 | |
| Benzylic Acid SCHEMBL9181980 | 0.82 | CYP2C9 (0.71) | CYP2C9CYP1A2HTTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6432923-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| US-6407065-B1 | PREVENT CELL ADHESION; ANTIINFLAMMTORY AGENTS, RESPIRATORY SYSTEM DISORDERS | NOVARTIS AG (CH) | 2002-06-18 | — | — | US | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6365619-B1 | CYCLIC OLIGOPEPTIDE VCAM-1 INHIBITOR; (S)-.BETA.-(3-METHOXYPROPYL) ((4-((2-METHYLPHENYLAMINOCARBONYLAMINO)-PHENYL) ACETYL)AMINO)ACETYL-AMINO-3,4-DIMETHOXY-BENZENEPROPANOIC ACID | NOVARTIS AG (CH) | 2002-04-02 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1049665-A1 | VLA-4 ANTAGONISTS | Novartis AG (Novartis SA) (Novartis Inc.) (CH) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037605-A1 | VLA-4 ANTAGONISTS | NOVARTIS AG (CH) | 1999-07-29 | — | — | WO | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | CYP2C9 4763/4885CYP1A2 4565/4885HTT 3064/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | CYP2C9 4763/4885CYP1A2 4565/4885HTT 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.